Aurinia Pharmaceuticals Inc. (AUPH)
Last updated: 2026-10-21 16:40:01. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Aurinia Pharmaceuticals Inc. (AUPH) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $16.98, with a market capitalization of $2.19B and a P/E ratio of 7.09. Over the past 52 weeks, its price has ranged from $11.48 to $19.25. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$2.19B | |
$16.73 | |
$33.97 | |
$1.41 | |
$16.74 | |
353.87K | |
961.46K | |
7.09 | |
$19.25 | |
$11.48 | |
-- | |
-- |
Aurinia Pharmaceuticals Inc. (AUPH) Stock Price Today
Aurinia Pharmaceuticals Inc. (AUPH) is currently trading at $16.98 as of 2026-10-21 16:39:00, up 1.43% ($0.24) from the previous close of $16.74
During today's regular trading session, AUPH has traded between $1.41 and $33.97, with a trading volume of 353.87K shares. The current price is near the middle of today's range.
Aurinia Pharmaceuticals Inc. (AUPH) 7-Day Stock Price Change
Over the past seven days, Aurinia Pharmaceuticals Inc. (AUPH) moved from $16.55 to $16.98, representing a gain of 2.60% ($0.43).
The stock traded between $16.11 and $17.30 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 848.06 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
AUPH 52-Week Price Position
Position in Range: 70.8%
AUPH is currently trading at $16.98, placing it 70.8% of the way from its 52-week low of $11.48 to its 52-week high of $19.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Aurinia Pharmaceuticals Inc. (AUPH)?
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Aurinia Pharmaceuticals Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 128 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Aurinia Pharmaceuticals Inc. (AUPH) Stock on MEXC
Eligible investors can buy real shares of Aurinia Pharmaceuticals Inc. (AUPH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Aurinia Pharmaceuticals Inc. (AUPH) stock price today?
2.Is AUPH stock going up or down today?
3.What is AUPH pre-market price?
4.What is AUPH after-hours price?
5.Is AUPH stock trading now?
6.Where does AUPH sit relative to its 52-week high and low?
7.What sector is Aurinia Pharmaceuticals Inc. in?
8.What is Aurinia Pharmaceuticals Inc.'s market capitalization and where is it listed?
9.How is AUPH valued in terms of P/E ratio and EPS?
10.Does Aurinia Pharmaceuticals Inc. pay a dividend?
Explore More US Stocks
Search Stocks
AUPH Stock Calculator
Estimate the value between AUPH shares and USD.
AUPH Shares to USD
1.00 AUPH shares = 16.98 USD
Calculations are estimates based on the latest available price and are for reference only.


